References: 1. Annegers JF, Hauser WA, Coan SP, Rocca WA: A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998, 338:20-24.
2. Vespa PM, Nuwer MR, Nenov V, Ronne-Engstrom E, Hovda DA, Bergsneider M, Kelly DF, Martin NA, Becker DP: Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999, 91:750-760.
3. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ: Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004, 62:1743-1748.
4. Jordan KG: Continuous EEG and evoked potential monitoring in the neuroscience intensive care unit. J Clin Neurophysiol 1993, 10:445-475.
5. Vespa PM, Nenov V, Nuwer MR: Continuous EEG monitoring in the intensive care unit: early findings and clinical efficacy. J Clin Neurophysiol 1999, 16:1-13.
6. Tay SK, Hirsch LJ, Leary L, Jette N, Wittman J, Akman CI: Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006, 47:1504-1509.
7. Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, Glenn TC, Martin N, Hovda D: Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 2007, 35:2830-2836.
8. Thapa A, Chandra SP, Sinha S, Sreenivas V, Sharma BS, Tripathi M: Post-traumatic seizures-A prospective study from a tertiary level trauma center in a developing country. Seizure 2010, 19:211-216.
9. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, et al: Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 2016.
10. Chadwick DW: Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985, 10:155-163.
11. DeVane CL: Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003, 37 Suppl 2:25-42.
12. Ebner T, Burchell B: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993, 21:50-55.
13. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI: Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993, 264:475-479.
14. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ: Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 2008, 83:595-600.
15. Klotz U: The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007, 46:271-279.
16. Loscher W, Klotz U, Zimprich F, Schmidt D: The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 50:1-23.
17. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK: Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006, 94:261-271.
18. Innocenti F, Liu W, Fackenthal D, Ramirez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, et al: Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 2008, 18:683-697.
19. Nagar S, Zalatoris JJ, Blanchard RL: Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 2004, 14:487-499.
20. Ibarra M, Vazquez M, Fagiolino P, Derendorf H: Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 2013, 40:479-486.
21. Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE: Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 2007, 29:571-575.
22. AAAM: Abbreviated Injury Scale (AIS) 2005 Manual. 1 edn: Association for the Advancement of Automotive Medicine; 2005.
23. Demetriades D, Kuncir E, Murray J, Velmahos GC, Rhee P, Chan L: Mortality prediction of head Abbreviated Injury Score and Glasgow Coma Scale: analysis of 7,764 head injuries. J Am Coll Surg 2004, 199:216-222.
24. Zehtabchi S, Soghoian S, Liu Y, Carmody K, Shah L, Whittaker B, Sinert R: The association of coagulopathy and traumatic brain injury in patients with isolated head injury. Resuscitation 2008, 76:52-56.
25. Alvarez M, Nava JM, Rue M, Quintana S: Mortality prediction in head trauma patients: performance of Glasgow Coma Score and general severity systems. Crit Care Med 1998, 26:142-148.
26. Brain Trauma F, American Association of Neurological S, Congress of Neurological S: Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007, 24 Suppl 1:S1-106.
27. Chu XM, Zhang LF, Wang GJ, Zhang SN, Zhou JH, Hao HP: Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 2012, 68:1395-1401.
28. Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y: The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010, 112:320-323.
29. Guo Y, Hu C, He X, Qiu F, Zhao L: Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 2012, 27:536-542.
30. Dikmen SS, Machamer JE, Winn HR, Anderson GD, Temkin NR: Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology 2000, 54:895-902.
31. Noai M, Soraoka H, Kajiwara A, Tanamachi Y, Oniki K, Nakagawa K, Ishitsu T, Saruwatari J: Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand 2016, 133:216-223.
32. Sutter R, Semmlack S, Kaplan PW: Nonconvulsive status epilepticus in adults - insights into the invisible. Nat Rev Neurol 2016, 12:281-293.
33. Tankanitlert J, Morales NP, Howard TA, Fucharoen P, Ware RE, Fucharoen S, Chantharaksri U: Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology 2007, 79:97-103.
34. Wang SL, Huang J, Lai MD, Tsai JJ: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995, 5:37-42.
35. Ronne-Engstrom E, Winkler T: Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity. Acta Neurol Scand 2006, 114:47-53.
36. Duncan R, Oto M, Martin E, Pelosi A: Late onset psychogenic nonepileptic attacks. Neurology 2006, 66:1644-1647.
37. Xing Y, Yang L, Wang L, Shao L, Wei Z, Xuan J, Li J, Qin S, Shu A, He L, Xing Q: Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics 2009, 10:741-752.
38. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, Shen JH: An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 2005, 85:502-506.
39. Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, Barbu V, Funck-Brentano C, Jaillon P, Becquemont L: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003, 17:373-376.
40. Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, Liou HH: Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 2011, 12:1107-1117.
41. Chatzistefanidis D, Lazaros L, Giaka K, Nakou I, Tzoufi M, Georgiou I, Kyritsis A, Markoula S: UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels. Pharmacogenomics 2016, 17:827-835.
42. Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, Muller M: Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol 2009, 65:1187-1193.
43. Sanchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Armijo JA: Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010, 19:93-101.
44. Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S, Pakdaman H, Kebriaeezadeh A: Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods 2010, 20:452-457.